Immunic, Inc. logo

Immunic, Inc.

NASDAQ:IMUX

Overview | Financials
Company Name Immunic, Inc.
Symbol IMUX
Currency USD
Price 1.18
Market Cap 106,293,220
Dividend Yield 0%
52-week-range 0.945 - 2.11
Industry Biotechnology
Sector Healthcare
CEO Dr. Daniel Vitt Ph.D.
Website https://www.immunic-therapeutics.com

An error occurred while fetching data.

About Immunic, Inc.

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune

Related Stocks

DermTech, Inc. logo

DermTech, Inc.

DMTK

0.094 USD

Pliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc.

PLRX

15 USD

Kronos Bio, Inc. logo

Kronos Bio, Inc.

KRON

0.825 USD

Marinus Pharmaceuticals, Inc. logo

Marinus Pharmaceuticals, Inc.

MRNS

0.345 USD

MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics

MLTX

51.78 USD

Personalis, Inc. logo

Personalis, Inc.

PSNL

4.55 USD

Sanara MedTech Inc. logo

Sanara MedTech Inc.

SMTI

35.24 USD

Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc.

LYRA

0.268 USD

Hyperfine, Inc. logo

Hyperfine, Inc.

HYPR

0.95 USD

Financials

Numbers are in millions USD

Numbers are in millions USD